Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and ...

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

HROW sets ambitious price targets in a new 3-year plan while showcasing strong drug growth and leveraging a proven model for ...

Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 10, William ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

Harrow has successfully leveraged its compounding pharmacy to drive rapid branded drug growth. My valuation suggests substantial upside if growth continues. Read the full stock analysis.

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Harrow (NASDAQ: HROW) just reported results for the second quarter of 2024. Harrow reported earnings per share of -6 cents. This was above the analyst estimate for EPS of -7 cents.

Moreover, HROW is currently trading at 98.4% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.